Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $1.01

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) gapped up prior to trading on Tuesday . The stock had previously closed at $1.01, but opened at $1.04. Adaptimmune Therapeutics shares last traded at $1.08, with a volume of 119,471 shares traded.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of Adaptimmune Therapeutics in a research report on Friday, December 29th. They issued a “hold” rating on the stock.

Adaptimmune Therapeutics Stock Down 5.3 %

The business’s 50-day simple moving average is $1.39 and its 200 day simple moving average is $0.92. The firm has a market capitalization of $1.07 billion, a P/E ratio of -1.96 and a beta of 2.39.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.12). Adaptimmune Therapeutics had a negative net margin of 188.90% and a negative return on equity of 155.39%. The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $4.80 million. Sell-side analysts predict that Adaptimmune Therapeutics plc will post -0.49 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ADAP. Barclays PLC purchased a new stake in shares of Adaptimmune Therapeutics during the second quarter valued at approximately $46,000. Marquette Asset Management LLC purchased a new stake in shares of Adaptimmune Therapeutics during the third quarter valued at approximately $77,000. Key Client Fiduciary Advisors LLC boosted its stake in shares of Adaptimmune Therapeutics by 6.4% during the fourth quarter. Key Client Fiduciary Advisors LLC now owns 336,620 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 20,295 shares during the period. Harbor Capital Advisors Inc. boosted its stake in shares of Adaptimmune Therapeutics by 9.9% during the fourth quarter. Harbor Capital Advisors Inc. now owns 147,732 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 13,317 shares during the period. Finally, Acuitas Investments LLC purchased a new stake in shares of Adaptimmune Therapeutics during the third quarter valued at approximately $374,000. 31.37% of the stock is currently owned by institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.